Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Urinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Urinary System Neoplasm

Cancer Family

Urinary System Neoplasm

CI-CAN-00000379Explore in graph →

Non-malignant964 active trials28 approved drugs109 evidence items

NCIt: C3431

Overview
Statistics
Survival
Genomics49
Variants & evidence109
Drugs26
Trials4238
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (244)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 244 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
· Tumour Biol · 2016 · PMID 26838030 · validated civic_curation pubmed
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.
· Clin Cancer Res · 2020 · PMID 32636318 · validated civic_curation pubmed
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
· Mod Pathol · 2019 · PMID 30980040 · validated civic_curation pubmed
SMARCB1/INI1 inactivation in renal medullary carcinoma.
· Histopathology · 2012 · PMID 22686875 · validated civic_curation pubmed
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
· Clin Genitourin Cancer · 2017 · PMID 28558987 · validated civic_curation pubmed
Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.
· Histopathology · 2020 · PMID 32590884 · validated

Showing 176–200 of 244 publications

← Previous
1
…
7
8
9
10
Next →

civic_curation

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

· Nature · 2018 · PMID 29420467 · validated civic_curation pubmed

Genotype-phenotype correlations in von Hippel-Lindau disease.

· Hum Mutat · 2007 · PMID 17024664 · validated civic_curation pubmed

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

· Cancer Discov · 2014 · PMID 24934408 · validated civic_curation pubmed

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.

· Pediatr Blood Cancer · 2018 · PMID 29893456 · validated civic_curation pubmed

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

· Cancer Discov · 2014 · PMID 24625776 · validated civic_curation pubmed

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

· Eur Urol · 2016 · PMID 25636205 · validated civic_curation pubmed

Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe.

· Hum Genet · 1996 · PMID 8707293 · validated civic_curation pubmed

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

· Am J Hum Genet · 1994 · PMID 7977367 · validated civic_curation pubmed

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

· Mod Pathol · 2018 · PMID 29099503 · validated civic_curation pubmed

Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.

· Pharmacogenetics · 2001 · PMID 11505222 · validated civic_curation pubmed

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

· Am J Surg Pathol · 2005 · PMID 15644781 · validated civic_curation pubmed

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

· Clin Cancer Res · 2009 · PMID 19228722 · validated civic_curation pubmed

Immunophenotype-Genotype Correlations in Clear Cell Sarcoma of Kidney-An Evaluation of Diagnostic Ancillary Studies.

· Pediatr Dev Pathol · 2020 · PMID 32364435 · validated civic_curation pubmed

Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story.

· J Pathol · 2016 · PMID 27000436 · validated civic_curation pubmed

Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion.

· Histopathology · 2018 · PMID 28833375 · validated civic_curation pubmed

BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney.

· Pediatr Blood Cancer · 2020 · PMID 31876361 · validated civic_curation pubmed

Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.

· Am J Surg Pathol · 2017 · PMID 28817404 · validated civic_curation pubmed